Study guide
15.3 Study and Site Closeout Procedures
Certified Clinical Research Coordinator CCRC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Concepts and Research Design
1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics
2 Chapter 2: Ethical Principles and Guidelines
2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent
3 Chapter 3: IRB/IEC Oversight and Participant Safety
3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting
4 Chapter 4: Participant Rights and Ethics
4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials
5 Chapter 5: Product Development and Regulatory Framework
5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)
6 Chapter 6: Investigational Product Accountability
6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction
7 Chapter 7: Regulatory Submissions and Actions
7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development
8 Chapter 8: Clinical Trial Operations and GCP Principles
8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight
9 Chapter 9: Essential Documents and Site Qualification
9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)
10 Chapter 10: Protocol Deviations and Amendments
10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control
11 Chapter 11: Monitoring Visits and Audits
11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits
12 Chapter 12: Study and Site Management - Startup
12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation
13 Chapter 13: Enrollment and Recruitment
13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics
14 Chapter 14: Daily Trial Coordination
14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)
15 Chapter 15: Quality Improvement and Site Closeout
15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures
16 Chapter 16: Source Documentation and Case Report Forms
16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems
17 Chapter 17: Data Management and Queries
17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails
18 Chapter 18: Data Privacy and Records Retention
18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics
15.3 Study and Site Closeout Procedures
Key Takeaways Explain This Topic AI
Data must be completely cleaned and queries resolved before site closeout
Final IP accountability requires reconciliation of all dispensed, returned, and remaining product
Essential records are kept for the required period under applicable regulations or until the sponsor says they are no longer needed, whichever is longer (ICH E6(R3) 2.12.12)
Last updated: October 2026
Study and Site Closeout Procedures
The end of a clinical trial involves much more than simply seeing the last patient for their last visit. Site closeout is a formal, rigorous process that ensures all study data is complete, regulatory obligations are met, and investigational products are properly reconciled. The Clinical Research Coordinator (CRC) orchestrates these final activities, working closely with the sponsor’s Clinical Research Associate (CRA) during the Site Closeout Visit (SCV).
Triggers for Site Closeout
Site closeout activities can be initiated under several circumstances:
Routine Completion: The site has successfully completed all protocol-required visits for all enrolled subjects, and the sponsor's database is ready to be locked.
Early Termination by Sponsor: The sponsor halts the trial early due to safety concerns (e.g., unacceptable toxicity), overwhelming efficacy, or lack of funding/commercial viability.
Early Termination by IRB or FDA: The study is suspended or terminated due to severe compliance issues or unmitigated risks to subjects.
Site-Specific Closure: The sponsor closes a specific site due to low enrollment or poor compliance, even while the overall trial continues globally.
Pre-Closeout Activities
Preparation for the SCV should begin weeks before the monitor arrives. The CRC focuses on three primary domains: Data, Investigational Product (IP), and Regulatory Documentation.
1. Data Cleaning and Query Resolution
Before a study can close, the data must be immaculate. The CRC must ensure that all Electronic Case Report Forms (eCRFs) are completed, all data queries generated by the sponsor or data management team are resolved, and the Principal Investigator (PI) has applied their electronic signature to the final data set. All Serious Adverse Events (SAEs) must be fully resolved or stabilized with final reports submitted.
2. Investigational Product (IP) Accountability
Every single pill, vial, or device shipped to the site must be accounted for. The CRC or Investigational Pharmacist must perform final reconciliation:
Ensure the amount of IP received matches the amount dispensed, returned by subjects, and remaining in inventory.
Document any missing or lost IP with appropriate explanations.
Follow sponsor instructions for the remaining IP: this usually involves either destroying the product on-site (with a certificate of destruction) or shipping it back to the sponsor.
3. Regulatory Binder Reconciliation
The Investigator Site File (ISF) must be complete and accurately reflect the timeline of the entire study. The CRC must file final versions of the delegation log, ensure all monitoring visit logs are signed, and verify that the site has copies of all IRB approvals and correspondence.
The Site Closeout Visit (SCV)
The SCV is the final monitoring visit conducted by the CRA. During this visit, the CRA will:
Conduct a final review of the regulatory binder.
Perform a final facility inspection (including the pharmacy and lab).
Verify the return or destruction of the IP.
Confirm that all biological samples have been shipped to the central laboratory.
Discuss record retention requirements and publication policies with the PI.
The PI is required to attend a closeout meeting with the CRA to review the final status of the study and acknowledge their ongoing regulatory responsibilities, particularly regarding record retention and FDA inspections.
Post-Closeout Regulatory Requirements
Even after the SCV is complete and the monitor has departed, the site has lingering regulatory obligations.
Final Report to the IRB
The PI is responsible for submitting a final study report to the Institutional Review Board (IRB). This report formally closes the study at the local level and typically includes the total number of subjects enrolled, a summary of all SAEs or unanticipated problems, and confirmation that all study activities have ceased.
Financial and Administrative Closure
The CRC and the site’s financial team must ensure all final invoices are submitted to the sponsor, outstanding subject stipends are paid, and study-specific vendor accounts (e.g., dry ice delivery) are canceled.
Record Retention Requirements
Closing the study does not mean throwing away the files. The site must securely store all study records in a manner that protects subject confidentiality while remaining accessible for future audits.
How long must records be kept?
ICH E6(R3): Keep essential records for the required retention period under applicable regulatory requirements or until the sponsor informs the site they are no longer needed, whichever is the longest (2.12.12).
FDA Regulations (Drugs): Investigational New Drug (IND) regulations require records to be retained for 2 years following the date a marketing application is approved for the drug for the indication being investigated. If no application is filed or approved, records must be kept for 2 years after the investigation is discontinued and the FDA is notified.
Sponsor Requirements: Clinical trial agreements (contracts) often require sites to retain records much longer than the FDA minimum, depending on other countries' regulations or company policies.
Site/Institutional Policies: The site's own institution may have specific retention periods.
Rule of Thumb: The site must follow the most stringent (longest) retention requirement among the FDA, sponsor, and local policies.
The site must never destroy study documents without explicit, written permission from the sponsor. If the PI leaves the institution, they must arrange for the transfer of custodial responsibility for the records and keep the sponsor informed of who is responsible for them (ICH E6(R3) 2.12.13), notifying the IRB too if its procedures require it.
In summary, site closeout is a critical phase that demands meticulous organization. By ensuring accurate data lock, complete IP accountability, and strict adherence to record retention rules, the CRC brings the clinical trial to a compliant and successful conclusion.